1
|
Huang Z, Qu E, Meng Y, Zhang M, Wei Q, Bai X, Zhang X. Deep learning-based pelvic levator hiatus segmentation from ultrasound images. Eur J Radiol Open 2022; 9:100412. [PMID: 35345817 PMCID: PMC8956942 DOI: 10.1016/j.ejro.2022.100412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 02/27/2022] [Accepted: 03/09/2022] [Indexed: 11/29/2022] Open
Abstract
Purpose To automatically segment and measure the levator hiatus with a deep learning approach and evaluate the performance between algorithms, sonographers, and different devices. Methods Three deep learning models (UNet-ResNet34, HR-Net, and SegNet) were trained with 360 images and validated with 42 images. The trained models were tested with two test sets. The first set included 138 images to evaluate the performance between the algorithms and sonographers. An independent dataset including 679 images assessed the performances of algorithms between different ultrasound devices. Four metrics were used for evaluation: DSC, HDD, the relative error of segmentation area, and the absolute error of segmentation area. Results The UNet model outperformed HR-Net and SegNet. It could achieve a mean DSC of 0.964 for the first test set and 0.952 for the independent test set. UNet was creditable compared with three senior sonographers with a noninferiority test in the first test set and equivalent in the two test sets collected by different devices. On average, it took two seconds to process one case with a GPU and 2.4 s with a CPU. Conclusions The deep learning approach has good performance for levator hiatus segmentation and good generalization ability on independent test sets. This automatic levator hiatus segmentation approach could help shorten the clinical examination time and improve consistency.
Collapse
Affiliation(s)
- Zeping Huang
- Department of Ultrasound, the Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, China
| | - Enze Qu
- Department of Ultrasound, the Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, China
| | - Yishuang Meng
- Philips (China) Investment Co. Ltd, 6F, Building A2, 718 Lingshi Road, Shanghai 200072, China
| | - Man Zhang
- Department of Ultrasound, the Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, China
| | - Qiuwen Wei
- Philips (China) Investment Co. Ltd, 6F, Building A2, 718 Lingshi Road, Shanghai 200072, China
| | - Xianghui Bai
- Philips (China) Investment Co. Ltd, 6F, Building A2, 718 Lingshi Road, Shanghai 200072, China
| | - Xinling Zhang
- Department of Ultrasound, the Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, China
| |
Collapse
|
2
|
Bartoli A, Fournel J, Maurin A, Marchi B, Habert P, Castelli M, Gaubert JY, Cortaredona S, Lagier JC, Million M, Raoult D, Ghattas B, Jacquier A. Value and prognostic impact of a deep learning segmentation model of COVID-19 lung lesions on low-dose chest CT. Res Diagn Interv Imaging 2022; 1:100003. [PMID: 37520010 PMCID: PMC8939894 DOI: 10.1016/j.redii.2022.100003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 03/02/2022] [Accepted: 03/09/2022] [Indexed: 12/23/2022]
Abstract
Objectives 1) To develop a deep learning (DL) pipeline allowing quantification of COVID-19 pulmonary lesions on low-dose computed tomography (LDCT). 2) To assess the prognostic value of DL-driven lesion quantification. Methods This monocentric retrospective study included training and test datasets taken from 144 and 30 patients, respectively. The reference was the manual segmentation of 3 labels: normal lung, ground-glass opacity(GGO) and consolidation(Cons). Model performance was evaluated with technical metrics, disease volume and extent. Intra- and interobserver agreement were recorded. The prognostic value of DL-driven disease extent was assessed in 1621 distinct patients using C-statistics. The end point was a combined outcome defined as death, hospitalization>10 days, intensive care unit hospitalization or oxygen therapy. Results The Dice coefficients for lesion (GGO+Cons) segmentations were 0.75±0.08, exceeding the values for human interobserver (0.70±0.08; 0.70±0.10) and intraobserver measures (0.72±0.09). DL-driven lesion quantification had a stronger correlation with the reference than inter- or intraobserver measures. After stepwise selection and adjustment for clinical characteristics, quantification significantly increased the prognostic accuracy of the model (0.82 vs. 0.90; p<0.0001). Conclusions A DL-driven model can provide reproducible and accurate segmentation of COVID-19 lesions on LDCT. Automatic lesion quantification has independent prognostic value for the identification of high-risk patients.
Collapse
Key Words
- ACE, angiotensin-converting enzyme
- Artificial intelligence
- BMI, body mass index
- CNN, convolutional neural network
- COVID-19
- COVID-19, coronavirus disease 2019
- CT-SS, chest tomography severity score
- Cons, consolidation
- DL, deep learning
- DSC, Dice similarity coefficient
- Deep learning
- Diagnostic imaging
- GGO, ground-glass opacity
- ICU, intensive care unit
- LDCT, low-dose computed tomography
- MAE, mean absolute error
- MVSF, mean volume similarity fraction
- Multidetector computed tomography
- ROC, receiver operating characteristic
Collapse
Affiliation(s)
- Axel Bartoli
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
- CRMBM - UMR CNRS 7339, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
| | - Joris Fournel
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
- CRMBM - UMR CNRS 7339, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
| | - Arnaud Maurin
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
| | - Baptiste Marchi
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
| | - Paul Habert
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
- LIEE, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
- CERIMED, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
| | - Maxime Castelli
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
| | - Jean-Yves Gaubert
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
- LIEE, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
- CERIMED, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
| | - Sebastien Cortaredona
- Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
- IRD, VITROME, Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
| | - Jean-Christophe Lagier
- Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
- IRD, MEPHI, Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
| | - Matthieu Million
- Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
- IRD, MEPHI, Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
| | - Didier Raoult
- Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
- IRD, MEPHI, Institut Hospitalo-Universitaire Méditerannée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France
| | - Badih Ghattas
- I2M - UMR CNRS 7373, Aix-Marseille University. CNRS, Centrale Marseille, 13453 Marseille, France
| | - Alexis Jacquier
- Department of Radiology, Hôpital de la Timone Adultes, AP-HM. 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France
- CRMBM - UMR CNRS 7339, Medical Faculty, Aix-Marseille University, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 05, France
| |
Collapse
|
3
|
Teunissen FR, Wortel RC, Wessels FJ, Claes A, van de Pol SMG, Rasing MJA, Meijer RP, van Melick HHE, de Boer JCJ, Verkooijen HM, van der Voort van Zyp JRN. Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer. Clin Transl Radiat Oncol 2022; 32:29-34. [PMID: 34825071 DOI: 10.1016/j.ctro.2021.11.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 10/18/2021] [Accepted: 11/08/2021] [Indexed: 11/20/2022] Open
Abstract
Interrater DSC of the NVB was 0.60 and 0.61 for the left and right side respectively. Interrater DSC of the IPA was 0.59 for the left and right side. Agreement was best for the inferior half (i.e. prostate apex to midgland) of the NVB. Agreement improved with MRI optimization and rater training.
Background and purpose Radiation damage to neural and vascular tissue, such as the neurovascular bundles (NVBs) and internal pudendal arteries (IPAs), during radiotherapy for prostate cancer (PCa) may cause erectile dysfunction. Neurovascular-sparing magnetic resonance-guided adaptive radiotherapy (MRgRT) aims to preserve erectile function after treatment. However, the NVBs and IPAs are not routinely contoured in current radiotherapy practice. Before neurovascular-sparing MRgRT for PCa can be implemented, the interrater agreement of the contouring of the NVBs and IPAs on pre-treatment MRI needs to be assessed. Materials and methods Four radiation oncologists independently contoured the prostate, NVB, and IPA in an unselected consecutive series of 15 PCa patients, on pre-treatment MRI. Dice similarity coefficients (DSCs) for pairwise interrater agreement of contours were calculated. Additionally, the DCS of a subset of the inferior half of the NVB contours (i.e. approximately prostate midgland to apex level) was calculated. Results Median overall interrater DSC for the left and right NVB was 0.60 (IQR: 0.54 – 0.68) and 0.61 (IQR: 0.53 – 0.69) respectively and for the left and right IPA 0.59 (IQR: 0.53 – 0.64) and 0.59 (IQR: 0.52 – 0.64) respectively. Median overall interrater DSC for the inferior half of the left NVB was 0.67 (IQR: 0.58 – 0.74) and 0.67 (IQR: 0.61 – 0.71) for the right NVB. Conclusion We found that the interrater agreement for the contouring of the NVB and IPA improved with enhancement of the MRI sequence as well as further training of the raters. The agreement was best in the subset of the inferior half of the NVB, where a good agreement is clinically most relevant for neurovascular-sparing MRgRT for PCa.
Collapse
Key Words
- CC, corpus cavernosum
- CT, computed tomography
- DSC, Dice similarity coefficient
- EBRT, external beam radiation therapy
- Erectile function sparing
- GRRAS, Guidelines for Reporting Reliability and Agreement Studies
- Gy, gray
- IPA, internal pudendal artery
- IQR, interquartile range
- Internal pudendal artery (IPA)
- Interrater agreement
- Localized prostate cancer (PCa)
- MRI, magnetic resonance imaging
- MRgRT, magnetic resonance-guided adaptive radiotherapy
- Magnetic resonance-guided radiotherapy (MRgRT)
- NCCN, National Comprehensive Cancer Network
- NVB, neurovascular bundle
- Neurovascular bundle (NVB)
- Neurovascular-sparing
- OAR, organs at risk
- PB, penile bulb
- PCa, prostate cancer
- PTV, planning target volume
Collapse
|
4
|
Aoyama T, Shimizu H, Kitagawa T, Yokoi K, Koide Y, Tachibana H, Suzuki K, Kodaira T. Comparison of atlas-based auto-segmentation accuracy for radiotherapy in prostate cancer. Phys Imaging Radiat Oncol 2021; 19:126-130. [PMID: 34485717 PMCID: PMC8397888 DOI: 10.1016/j.phro.2021.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 08/07/2021] [Accepted: 08/11/2021] [Indexed: 11/30/2022]
Abstract
Auto-contouring accuracy and contouring time were evaluated using two procedures. Dice coefficient was better for the multiple atlases procedure than for one atlas. Contouring time of the multiple atlases procedure is clinically acceptable.
Atlas-based auto-segmentation (ABS) procedure used in radiotherapy can be classified into two groups, one using one atlas per patient (sSM) and the other using multiple atlases (sMM). This study evaluated auto-contouring accuracy and contouring time in patients with prostate cancer using the two procedures. The Dice similarity coefficient of sMM was significantly better than that of sSM (prostate [median, 0.81 (range, 0.66–0.91) vs. 0.64 (0.27–0.71), p < 0.01], seminal vesicles [0.49 (0.31–0.80) vs. 0.18 (0.01–0.60), p < 0.05], and rectum [0.81 (0.37–0.91) vs. 0.57 (0.31–0.77), p < 0.01]). The median contouring times were 2.6 (sMM) and 1.3 min (sSM).
Collapse
Affiliation(s)
- Takahiro Aoyama
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan.,Graduate School of Medicine, Aichi Medical University, 1-1 Yazako-karimata, Nagakute, Aichi 480-1195, Japan
| | - Hidetoshi Shimizu
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| | - Tomoki Kitagawa
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| | - Kazushi Yokoi
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| | - Yutaro Koide
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| | - Hiroyuki Tachibana
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| | - Kojiro Suzuki
- Department of Radiology, Aichi Medical University, 1-1 Yazako-karimata, Nagakute, Aichi 480-1195, Japan
| | - Takeshi Kodaira
- Department of Radiation Oncology, Aichi Cancer Centre, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan
| |
Collapse
|
5
|
Esteyrie V, Gleyzolle B, Lusque A, Graff P, Modesto A, Rives M, Lapeyre M, Desrousseaux J, Graulières E, Hangard G, Arnaud FX, Ferrand R, Delord JP, Poublanc M, Mounier M, Filleron T, Laprie A. The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer. Clin Transl Radiat Oncol 2019; 16:34-39. [PMID: 30949592 PMCID: PMC6429538 DOI: 10.1016/j.ctro.2019.02.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 02/22/2019] [Accepted: 02/23/2019] [Indexed: 11/25/2022] Open
Abstract
During exclusive curative radiotherapy for head and neck tumors, the patient's organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools are needed to define the optimal time for replanning, and 2) the subsequent workflow is time-consuming. We designed a prospective study to evaluate 1) the validity of automatically deformed contours on the daily MVCT, in order to safely use the "dose-of the day" tool to check daily if replanning is necessary; 2) the automatically deformed contours on the replanning CT and the time gained in the replanning workflow. Forty-eight patients with T3-T4 and/or involved node >2 cm head and neck squamous cell carcinomas, planned for curative radiotherapy without surgery, will be enrolled. They will undergo treatment with helical IMRT including daily repositioning MVCTs. The contours proposed will be compared weekly on intermediate planning CTs (iCTs) on weeks 3, 4, 5 and 6. On these iCTs both manual recontouring and automated deformable registration of the initial contours will be compared with the contours automatically defined on the MVCT. The primary objective is to evaluate the Dice similarity coefficient (DSC) of the volumes of each parotid gland. The secondary objectives will evaluate, for target volumes and all OARs: the DSC, the mean distance to agreement, and the average surface-to-surface distance. Time between the automatic and the manual recontouring workflows will be compared.
Collapse
Key Words
- ART, adaptive radiotherapy
- CT, computed tomography
- CTV, clinical target volume
- DIR, deformable image registration
- DSC, Dice similarity coefficient
- GTV, gross tumor volume
- H&N, head and neck
- ICRU, international commission on radiation units and measurements
- IGRT, image-guided radiotherapy
- IMRT, intensity-modulated radiotherapy
- IUCT, Institut Universitaire du cancer de Toulouse
- MVCT, megavoltage computed tomography
- OAR, organ at risk
- PET, positron emission tomography
- PTV, planning target volume
- iCT, intermediate computed tomography
Collapse
Affiliation(s)
- Vincent Esteyrie
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | | | - Amélie Lusque
- Biostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse - Oncopole Toulouse, France
| | - Pierre Graff
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | - Anouchka Modesto
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | - Michel Rives
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | - Michel Lapeyre
- Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Jacques Desrousseaux
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| | - Eliane Graulières
- Engineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Gregory Hangard
- Engineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - François-Xavier Arnaud
- Engineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Regis Ferrand
- Engineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Jean-Pierre Delord
- Clinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Muriel Poublanc
- Clinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Muriel Mounier
- Clinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole. Toulouse, France
| | - Thomas Filleron
- Biostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse - Oncopole Toulouse, France
| | - Anne Laprie
- Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France
| |
Collapse
|
6
|
Franco P, Arcadipane F, Trino E, Gallio E, Martini S, Iorio GC, Piva C, Moretto F, Ruo Redda MG, Verna R, Tseroni V, Bona C, Pozzi G, Fiandra C, Ragona R, Bertetto O, Ricardi U. Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. Clin Transl Radiat Oncol 2018; 11:33-39. [PMID: 29928706 PMCID: PMC6008279 DOI: 10.1016/j.ctro.2018.06.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Revised: 06/05/2018] [Accepted: 06/08/2018] [Indexed: 02/08/2023] Open
Abstract
Objective Delineation of treatment volumes is a major source of uncertainties in radiotherapy (RT). This is also true for rectal cancer patients undergoing neoadjuvant RT, with a potential impact on treatment quality. We investigated the role of the digital platform Anatom-e (Anatom-e Information Sytems Ltd., Houston, Texas) in increasing the compliance to follow a specific treatment protocol in a multicentric setting. Materials and methods Two clinical cases of locally advanced rectal cancer were chosen. Participants were instructed to follow the 2009 Radiation Therapy Oncology Group consensus atlas and asked to manually segment clinical target volumes (CTVs), for both patient 1 and 2, on day 1 with and without the use of Anatom-e. After one week (day 2), the same radiation oncologist contoured again, with and without Anatom-e, the same CT series. Intraobserver (Intra-OV) and interobserver (Inter-OV) variability were evaluated with the Dice similarity coefficient (DSC), the Hausdorff distance (HD) and mean distance to agreement (MDA). Results For clinical case 1, no significant difference was found for Intra-OV and Inter-OV. For clinical case 2, no significant difference was found for Intra-OV but a statistically significant difference was found for Inter-OV in DSC when using or not the platform. Mean DCS was 0.65 (SD: ±0.64; range: 0.58-0.79) for day 1 vs reference volume without Anatom-e and 0.72 (SD: ±0.39; range: 0.67-0.77) (p = 0.03) with it. Mean MDA was lower with Anatom-e (3.61; SD: ±1.33; range: 2.85-4.78) than without (4.14; SD: ±2.97; range: 2.18-5.21), with no statistical significance (p = 0.21) The use of Anatom-e decreased the SD from 2.97 to 1.33. Mean HD was lower with Anatom-e (26.06; SD: ±2.05; range: 24.08-32.62), with no statistical significance (p = 0.14) compared to that without (31.39; SD: ±1.31; range: 26.14-48.72). Conclusions The use of Anatom-e decreased the Inter-OV in the CTV delineation process for locally advanced rectal cancer with complex disease presentation planned for neoadjuvant RT. This system may be potentially helpful in increasing the compliance to follow shared guidelines and protocols.
Collapse
Key Words
- AJCC/UICC, American Joint Committee on Cancer/Union Internationale Contre le Cancer
- CHT, chemotherapy
- CT, computed tomography
- CTV, clinical target volume
- Contouring
- DSC, Dice similarity coefficient
- GTV, gross tumor volume
- HD, Hausdorff distance
- Inter-OV, inter-observer variability
- Interobserver variability
- Intra-OV, intra-observer variability
- MDA, mean distance to agreement
- MR, magnetic resonance imaging
- Neoadjuvant radiotherapy
- OARs, organs at risk
- RT, radiotherapy
- RTOG, Radiation Therapy Oncology Group
- Rectal cancer
- Ros, radiation oncologists
- SD, standard deviation
- SWOG, Radiation Committee of the Southwest Oncology Group
- Target volume delineation
- VMAT, volumetric modulated arc therapy
Collapse
Affiliation(s)
- Pierfrancesco Franco
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | - Francesca Arcadipane
- Department of Oncology, Radiation Oncology, AOU Citta' della Salute e della Scienza, Turin, Italy
| | - Elisabetta Trino
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | - Elena Gallio
- Department of Medical Physics, AOU Citta' della Salute e della Scienza, Turin, Italy
| | - Stefania Martini
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | - Giuseppe Carlo Iorio
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | - Cristina Piva
- Department of Radiation Oncology, Ivrea Community Hospital, Ivrea, Italy
| | - Francesco Moretto
- Department of Radiation Oncology, 'Cardinal Massaia' Community Hospital, Asti, Italy
| | - Maria Grazia Ruo Redda
- Department of Oncology, Radiation Oncology, University of Turin, AO Ordine Mauriziano, Turin, Italy
| | - Roberta Verna
- Department of Radiation Oncology, AOU San Luigi Gonzaga, Orbassano (TO), Italy
| | - Vassiliki Tseroni
- Department of Oncology, Radiation Oncology, AOU Citta' della Salute e della Scienza, Presidio San Giovanni Antica Sede, Turin, Italy
| | - Cristina Bona
- Department of Radiation Oncology, ASL Verbano Cusio Ossola, Verbania, Italy
| | - Gabriele Pozzi
- Department of Radiation Oncology, AO 'SS Antonio e Biagio e Cesare Arrigo', Alessandria, Italy
| | - Christian Fiandra
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | - Riccardo Ragona
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| | | | - Umberto Ricardi
- Department of Oncology, Radiation Oncology, University of Turin, AOU Citta' della salute e della Scienza, Turin, Italy
| |
Collapse
|